Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
- PMID: 17969020
- DOI: 10.1002/ana.21289
Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
Abstract
Although the cause of multiple sclerosis (MS) has remained obscure, many findings support an autoimmune pathogenesis on the background of a complex interaction between multiple genes and environmental factors. Accordingly, targeting the immune system has been a rational approach for the treatment of MS. The development of disease-modifying immunomodulatory drugs with partial efficacy, coupled with advances in understanding the pathophysiology and pathology of MS, has provided momentum to explore more specific and hopefully more effective immune-based therapeutic strategies. With increased knowledge and appreciation of the contribution of neurodegenerative processes to disease pathology, the therapeutic challenges, however, have become even more formidable. Future treatments will likely need both to target inflammation and to focus on promotion of neuroprotection and repair. In this review, we discuss the most promising therapeutic approaches for MS currently in the pipeline.
Similar articles
-
The future of multiple sclerosis treatment.J Neurol Sci. 2009 Feb 1;277 Suppl 1:S55-61. doi: 10.1016/S0022-510X(09)70015-2. J Neurol Sci. 2009. PMID: 19200869
-
Emerging therapies in multiple sclerosis.Expert Opin Emerg Drugs. 2005 Nov;10(4):797-816. doi: 10.1517/14728214.10.4.797. Expert Opin Emerg Drugs. 2005. PMID: 16262563 Review.
-
Advancement of therapies for neuroprotection in multiple sclerosis.Expert Rev Neurother. 2008 Sep;8(9):1355-66. doi: 10.1586/14737175.8.9.1355. Expert Rev Neurother. 2008. PMID: 18759548 Review.
-
Linkage between immunomodulation, neuroprotection and neurogenesis.Drug News Perspect. 2009 Jul-Aug;22(6):301-12. doi: 10.1358/dnp.2009.22.6.1395253. Drug News Perspect. 2009. PMID: 19771319 Review.
-
Immunotherapy of multiple sclerosis--current practice and future directions.J Rehabil Res Dev. 2002 Mar-Apr;39(2):273-85. J Rehabil Res Dev. 2002. PMID: 12051470 Review.
Cited by
-
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101. doi: 10.1097/WNF.0b013e3181cbf825. Clin Neuropharmacol. 2010. PMID: 20061941 Free PMC article. Review.
-
Development of oral cladribine for the treatment of multiple sclerosis.J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0. J Neurol. 2010. PMID: 19921304 Review.
-
Fingolimod Enhances Oligodendrocyte Differentiation of Transplanted Human Induced Pluripotent Stem Cell-Derived Neural Progenitors.Iran J Pharm Res. 2018 Fall;17(4):1444-1457. Iran J Pharm Res. 2018. PMID: 30568702 Free PMC article.
-
The Potential Role of T Helper Cell 22 and IL-22 in Immunopathogenesis of Multiple Sclerosis.Innov Clin Neurosci. 2016 Aug 1;13(7-8):30-6. eCollection 2016 Jul-Aug. Innov Clin Neurosci. 2016. PMID: 27672486 Free PMC article. Review.
-
Animal models of multiple sclerosis--potentials and limitations.Prog Neurobiol. 2010 Nov;92(3):386-404. doi: 10.1016/j.pneurobio.2010.06.005. Epub 2010 Jun 15. Prog Neurobiol. 2010. PMID: 20558237 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical